Upload
aditya-ilham
View
237
Download
0
Embed Size (px)
Citation preview
7/30/2019 PPT DR LENA
1/24
MEDICAL FACULTY TRISAKTI
UNIVERSITYJAKARTA, 10 JANUARY 2012
By : Aditya Ilham Noer
030.08.086
CORRELATION BETWEEN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE AND VITAMIN D
7/30/2019 PPT DR LENA
2/24
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD)makes it hard for you to breathe. Coughing up mucus
is often the first sign of COPD. Chronic bronchitis and
emphysema are common COPDs. Cigarette smoking
is the most common cause of COPD. Breathing inother kinds of irritants, like pollution, dust or
chemicals, may also cause or contribute to COPD.
Quitting smoking is the best way to avoid developing
COPD.
Vitamin D-binding protein (DBP) genetic
polymorphisms have been associated with chronic
obstructive pulmonary disease (COPD). DBP has an
indirect role in macrophage activation; thus it was
http://www.nlm.nih.gov/medlineplus/chronicbronchitis.htmlhttp://www.nlm.nih.gov/medlineplus/emphysema.htmlhttp://www.nlm.nih.gov/medlineplus/quittingsmoking.htmlhttp://www.nlm.nih.gov/medlineplus/quittingsmoking.htmlhttp://www.nlm.nih.gov/medlineplus/quittingsmoking.htmlhttp://www.nlm.nih.gov/medlineplus/quittingsmoking.htmlhttp://www.nlm.nih.gov/medlineplus/emphysema.htmlhttp://www.nlm.nih.gov/medlineplus/chronicbronchitis.html7/30/2019 PPT DR LENA
3/24
COPD
is the co-occurrence of chronic bronchitis andemphysema, a pair of commonly co-existing diseases
of the lungs in which the airways become narrowed.[1]
This leads to a limitation of the flow of air to and from
the lungs, causing shortness of breath (dyspnea). Inclinical practice, COPD is defined by its
characteristically low airflow on lung function tests.
Classification
1. Chronic bronchitis
2. Emphysema
http://en.wikipedia.org/wiki/Chronic_bronchitishttp://en.wikipedia.org/wiki/Emphysemahttp://en.wikipedia.org/wiki/Airwayshttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Shortness_of_breathhttp://en.wikipedia.org/wiki/Lung_function_testhttp://en.wikipedia.org/wiki/Lung_function_testhttp://en.wikipedia.org/wiki/Lung_function_testhttp://en.wikipedia.org/wiki/Lung_function_testhttp://en.wikipedia.org/wiki/Lung_function_testhttp://en.wikipedia.org/wiki/Lung_function_testhttp://en.wikipedia.org/wiki/Shortness_of_breathhttp://en.wikipedia.org/wiki/Shortness_of_breathhttp://en.wikipedia.org/wiki/Shortness_of_breathhttp://en.wikipedia.org/wiki/Shortness_of_breathhttp://en.wikipedia.org/wiki/Shortness_of_breathhttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Airwayshttp://en.wikipedia.org/wiki/Emphysemahttp://en.wikipedia.org/wiki/Chronic_bronchitishttp://en.wikipedia.org/wiki/Chronic_bronchitishttp://en.wikipedia.org/wiki/Chronic_bronchitis7/30/2019 PPT DR LENA
4/24
Chronic Bronchitis
Lung damage and inflammation in the large airways
results in chronic bronchitis. Chronic bronchitis isdefined in clinical terms as a cough with sputum
production on most days for 3 months of a year, for 2
consecutive years.
Emphysema
Lung damage and inflammation of the air sacs
(alveoli) results in emphysema. Emphysema is
defined as enlargement of the air spaces distal to the
terminal bronchioles, with destruction of their walls.
http://en.wikipedia.org/wiki/Sputumhttp://en.wikipedia.org/wiki/Alveolihttp://en.wikipedia.org/wiki/Emphysemahttp://en.wikipedia.org/wiki/Distalhttp://en.wikipedia.org/wiki/Terminal_bronchioleshttp://en.wikipedia.org/wiki/Terminal_bronchioleshttp://en.wikipedia.org/wiki/Terminal_bronchioleshttp://en.wikipedia.org/wiki/Terminal_bronchioleshttp://en.wikipedia.org/wiki/Distalhttp://en.wikipedia.org/wiki/Emphysemahttp://en.wikipedia.org/wiki/Alveolihttp://en.wikipedia.org/wiki/Sputum7/30/2019 PPT DR LENA
5/24
Sign and Symptom
History of cigarette smoking.
Chronic cough and sputum production (in chronic
bronchitis)
Dyspnea Rhonchi, decreased intensity of breath sounds, and
prolonged expiration on physical examination
Airflow limitation on pulmonary function testing that is
not fully reversible and most often progressive.
http://en.wikipedia.org/wiki/Dyspneahttp://en.wikipedia.org/wiki/Rhonchihttp://en.wikipedia.org/wiki/Exhalationhttp://en.wikipedia.org/wiki/Exhalationhttp://en.wikipedia.org/wiki/Rhonchihttp://en.wikipedia.org/wiki/Dyspnea7/30/2019 PPT DR LENA
6/24
Etilogy
Occupational exposures
Intense and prolonged exposure to workplace dusts
found in coal mining, gold mining, and the cotton
textile industry and chemicals such as cadmium,
isocyanates, and fumes from welding have been
implicated in the development of airflow obstruction,
even in nonsmokers. Workers who smoke and are
exposed to these particles and gases are even more
likely to develop COPD.
Air pollution
Studies in many countries have found people who live
in large cities have a higher rate of COPD comparedto eo le who live in rural areas. Urban air ollution
http://en.wikipedia.org/wiki/Coal_mininghttp://en.wikipedia.org/wiki/Gold_mininghttp://en.wikipedia.org/wiki/Cadmiumhttp://en.wikipedia.org/wiki/Isocyanateshttp://en.wikipedia.org/wiki/Weldinghttp://en.wikipedia.org/wiki/Air_pollutionhttp://en.wikipedia.org/wiki/Air_pollutionhttp://en.wikipedia.org/wiki/Air_pollutionhttp://en.wikipedia.org/wiki/Air_pollutionhttp://en.wikipedia.org/wiki/Weldinghttp://en.wikipedia.org/wiki/Isocyanateshttp://en.wikipedia.org/wiki/Cadmiumhttp://en.wikipedia.org/wiki/Gold_mininghttp://en.wikipedia.org/wiki/Gold_mininghttp://en.wikipedia.org/wiki/Gold_mininghttp://en.wikipedia.org/wiki/Coal_mininghttp://en.wikipedia.org/wiki/Coal_mininghttp://en.wikipedia.org/wiki/Coal_mining7/30/2019 PPT DR LENA
7/24
Genetics
Alpha 1-antitrypsin deficiency is a genetic conditionthat is responsible for about 2% of cases of COPD. In
this condition, the body does not make enough of aprotein, alpha 1-antitrypsin. Alpha 1-antitrypsinprotects the lungs from damage caused by proteaseenzymes, such as elastase and trypsin, that can be
released as a result of an inflammatory response totobacco smoke.[7]
Autoimmune disease
There is mounting evidence that there may be an
autoimmune component to COPD, triggered bylifelong smoking. Many individuals with COPD whohave stopped smoking have active inflammation inthe lungs. The disease may continue to get worse formany years after stopping smoking due to this
ongoing inflammation. This sustained inflammation is
http://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsinhttp://en.wikipedia.org/wiki/Proteasehttp://en.wikipedia.org/wiki/Enzymeshttp://en.wikipedia.org/wiki/Elastasehttp://en.wikipedia.org/wiki/Trypsinhttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Autoantibodieshttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Trypsinhttp://en.wikipedia.org/wiki/Elastasehttp://en.wikipedia.org/wiki/Enzymeshttp://en.wikipedia.org/wiki/Proteasehttp://en.wikipedia.org/wiki/Alpha_1-antitrypsinhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsinhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsinhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsinhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsinhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiencyhttp://en.wikipedia.org/wiki/Alpha_1-antitrypsin_deficiency7/30/2019 PPT DR LENA
8/24
PHATOPHYSIOLOGY Narrowing of the airways reduces the rate at which air can flow to
and from the air sacs (alveoli) and limits the effectiveness of thelungs. In COPD, the greatest reduction in air flow occurs whenbreathing out (during expiration) because the pressure in thechest tends to compress rather than expand the airways. In
theory, air flow could be increased by breathing more forcefully,increasing the pressure in the chest during expiration. In COPD,there is often a limit to how much this can actually increase airflow, a situation known as expiratory flow limitation.[5]
If the rate of airflow is too low, a person with COPD may not be
able to completely finish breathing out (expiration) before he orshe needs to take another breath. This is particularly commonduring exercise, when breathing has to be faster. A little of the airof the previous breath remains within the lungs when the nextbreath is started, resulting in an increase in the volume of air inthe lungs, a process called dynamic hyperinflation.[5]
Dynamic hyperinflation is closely linked to dyspnea in COPD. It is
http://en.wikipedia.org/wiki/Alveolihttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Hyperaerationhttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Dyspneahttp://en.wikipedia.org/wiki/Dyspneahttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Hyperaerationhttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Alveoli7/30/2019 PPT DR LENA
9/24
DIAGNOSISChest X-ray
Spirometry The diagnosis of COPD is confirmed by spirometry, a
test that measures the forced expiratory volume inone second (FEV1), which is the greatest volume of
air that can be breathed out in the first second of alarge breath
More specifically, the diagnosis of COPD is madewhen the FEV1/FVC ratio is
7/30/2019 PPT DR LENA
10/24
Spirometry can help to determine the severity of COPD.[4]
The FEV1 (measured after bronchodilator medication) is
expressed as a percentage of a predicted "normal" valuebased on a person's age, gender, height and weight:
1. Severity of COPD (GOLD scale) = FEV1 % predicted
2. Mild (GOLD 1) = 80
3. Moderate (GOLD 2) = 5079
4. Severe (GOLD 3)3 = 049
5. Very severe (GOLD 4) =
7/30/2019 PPT DR LENA
11/24
TREATMENT
The goals of COPD treatment are: to prevent further deterioration in lung function;
to alleviate symptoms;
to improve performance of daily activities and quality oflife.
The treatment strategies include:
quitting cigarette smoking;
taking medications to dilate airways (bronchodilators) and
decrease airway inflammation; vaccination against flu influenza and pneumonia;
regular oxygen supplementation; and
pulmonary rehabilitation.
http://www.medicinenet.com/script/main/art.asp?articlekey=11815http://www.medicinenet.com/script/main/art.asp?articlekey=11815http://www.medicinenet.com/script/main/art.asp?articlekey=9098http://www.medicinenet.com/script/main/art.asp?articlekey=9097http://www.medicinenet.com/script/main/art.asp?articlekey=9097http://www.medicinenet.com/script/main/art.asp?articlekey=9098http://www.medicinenet.com/script/main/art.asp?articlekey=9098http://www.medicinenet.com/script/main/art.asp?articlekey=9098http://www.medicinenet.com/script/main/art.asp?articlekey=11815http://www.medicinenet.com/script/main/art.asp?articlekey=11815http://www.medicinenet.com/script/main/art.asp?articlekey=11815http://www.medicinenet.com/script/main/art.asp?articlekey=11815http://www.medicinenet.com/script/main/art.asp?articlekey=118157/30/2019 PPT DR LENA
12/24
Bronchodilators
Bronchodilators are medicines that relax smoothmuscle around the airways, increasing the calibre of
the airways and improving air flow. They can reducethe symptoms of shortness of breath, wheeze andexercise limitation, resulting in an improved quality oflife for people with COPD.
There are two major types of bronchodilator,1. 2 agonists and
2. anticholinergics.
Anticholinergics appear to be superior to 2 agonists
in COPD. Anticholinergics reduce respiratory deathswhile 2 agonists have no effect on respiratorydeaths.
http://en.wikipedia.org/wiki/Bronchodilatorshttp://en.wikipedia.org/wiki/Smooth_musclehttp://en.wikipedia.org/wiki/Smooth_musclehttp://en.wikipedia.org/wiki/Smooth_musclehttp://en.wikipedia.org/wiki/Smooth_musclehttp://en.wikipedia.org/wiki/Smooth_musclehttp://en.wikipedia.org/wiki/Bronchodilators7/30/2019 PPT DR LENA
13/24
2 agonists
2 agonists stimulate 2 receptors on airway smooth
muscles, causing them to relax. There are several 2
agonists available. Salbutamol (common brand name:
Ventolin) and terbutaline are widely used short acting 2
agonists and provide rapid relief of COPD symptoms.
Long acting 2 agonists (LABAs) such as salmeterol and
formoterol are used as maintenance therapy and lead toimproved airflow, exercise capacity, and quality of life.
Anticholinergics
Anticholinergic drugs cause airway smooth muscles torelax by blocking stimulation from cholinergic nerves.
Ipratropium provides short-acting rapid relief of COPD
symptoms. Tiotropium is a long-acting anticholinergic
whose regular use is associated with improvements in
http://en.wikipedia.org/wiki/Receptor_(biochemistry)http://en.wikipedia.org/wiki/Salbutamolhttp://en.wikipedia.org/wiki/Terbutalinehttp://en.wikipedia.org/wiki/Salmeterolhttp://en.wikipedia.org/wiki/Formoterolhttp://en.wikipedia.org/wiki/Cholinergichttp://en.wikipedia.org/wiki/Ipratropiumhttp://en.wikipedia.org/wiki/Tiotropiumhttp://en.wikipedia.org/wiki/Tiotropiumhttp://en.wikipedia.org/wiki/Ipratropiumhttp://en.wikipedia.org/wiki/Cholinergichttp://en.wikipedia.org/wiki/Formoterolhttp://en.wikipedia.org/wiki/Salmeterolhttp://en.wikipedia.org/wiki/Terbutalinehttp://en.wikipedia.org/wiki/Salbutamolhttp://en.wikipedia.org/wiki/Receptor_(biochemistry)7/30/2019 PPT DR LENA
14/24
Corticosteroids
Corticosteroids are used in tablet or inhaled form
to treat and prevent acute exacerbations ofCOPD. Well-inhaled corticosteroids (ICS) have
not been shown to be of benefit for people with
mild COPD, however, they have been shown to
decrease acute exacerbations in those with eithermoderate or severe COPD.
http://en.wikipedia.org/wiki/Corticosteroidhttp://en.wikipedia.org/wiki/Corticosteroid7/30/2019 PPT DR LENA
15/24
PROGNOSIS
COPD usually gradually gets worse over time andcan lead to death. The rate at which it gets worsevaries between individuals. The factors thatpredict a poorer prognosis are:[6]
Severe airflow obstruction (low FEV1) Poor exercise capacity
Shortness of breath
Significantly underweight or overweight
Complications like respiratory failure or corpulmonale
Continued smoking
Frequent acute exacerbations
http://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseasehttp://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease7/30/2019 PPT DR LENA
16/24
VITAMIN D
Definition
Vitamin D is a fat-soluble vitamin. Fat-soluble vitamins
are stored in the body's fatty tissue.
Function
Vitamin D helps the body absorb calcium. Calcium
and phosphate are two minerals that are essential for
normal bone formation.
Throughout childhood, your body uses these mineralsto produce bones. If you do not get enough calcium,
or if your body does not absorb enough calcium from
your diet, bone production and bone tissues may
suffer.
http://www.nlm.nih.gov/medlineplus/ency/article/002412.htmhttp://www.nlm.nih.gov/medlineplus/ency/article/002412.htm7/30/2019 PPT DR LENA
17/24
FOOD SOURCES
The body makes vitamin D when the skin is directlyexposed to the sun. That is why it is often called the"sunshine" vitamin. Most people meet at least some oftheir vitamin D needs this way.
Very few foods naturally contain vitamin D. As a result,many foods are fortified with vitamin D. Fortified meansthat vitamins have been added to the food.
It can be very hard to get enough vitamin D from food
sources alone. As a result, some people may need totake a vitamin D supplement. Vitamin D found insupplements and fortified foods comes in two differentforms:
D2 (ergocalciferol)
D3 (cholecalciferol)
7/30/2019 PPT DR LENA
18/24
FOOD SOURCESDairy products
Cheese
Butter Cream
Fortified milk (allmilk in the U.S. isfortified withvitamin D)
Fatty fish (suchas tuna,
salmon, andmackerel)
Fortifiedbreakfastcereals,
margarine, andsoy milk (check
the Nutrition
Fact Panel onthe food label)
7/30/2019 PPT DR LENA
19/24
Too much vitamin D can make the intestines absorb too
much calcium. This may cause high levels of calcium in the
blood. High blood calcium can lead to:
Confusionand
disorientation
Damage tothe kidneys
Calciumdeposits insoft tissues
such as theheart andlungs
Kidney stones
http://www.nlm.nih.gov/medlineplus/ency/article/000458.htmhttp://www.nlm.nih.gov/medlineplus/ency/article/000458.htm7/30/2019 PPT DR LENA
20/24
RECOMMENDATIONS
Ten to 15 minutes of sunshine three times weekly isenough to produce the body's requirement of vitamin
D. The sun needs to shine on the skin of your face,
arms, back, or legs (without sunscreen). Because
exposure to sunlight is a risk for skin cancer, youshould use sunscreen after a few minutes in the sun.
7/30/2019 PPT DR LENA
21/24
Infants (adequate intake of vitamin D)
0 - 6 months: 400 IU (10 micrograms (mcg) per day) 7 - 12 months: 400 IU (5 mcg/day)
Children
1 - 3 years: 600 IU (15 mcg/day) 4 - 8 years: 600 IU (15 mcg/day)
Older children and adults
9 - 70 years: 600 IU (15 mcg/day)
Adults over 70 years: 800 IU (20 mcg/day)
Pregnancy and breast-feeding: 600 IU (15 mcg/day)
7/30/2019 PPT DR LENA
22/24
CORRELATION BETWEEN VITAMIN D AND COPD
7/30/2019 PPT DR LENA
23/24
CONCLUSION Vitamin D deficiency occurs frequently in COPD and
correlates with severity of COPD. The data warrantvitamin D supplementation in patients with severeCOPD, especially in those carrying at-risk rs7041
variants. whether prevention of vitamin D deficiencyor its supplementation can reverse the course ofCOPD. Vitamin D and its deficiency are intricatelyinvolved in many of the pathogenic mechanisms ofCOPD and its severity increases proportionately with
the severity of deficiency. The authors describedseveral of the chemical and biological pathways bywhich vitamin D supplementation may benefitpatients. They concluded there is urgent need for
controlled trials to investigate the efficacy of vitamin Dfor reversing the disease's progression.
7/30/2019 PPT DR LENA
24/24
REFERENCES Nathell, L.; Nathell, M.; Malmberg, P.; Larsson, K. (2007). "COPD diagnosis related to different guidelines and
spirometry techniques". Respiratory research8 (1): 89.
Simpson CR, Hippisley-Cox J, Sheikh A (2010). "Trends in the epidemiology of chronic obstructive pulmonarydisease in England: a national study of 51 804 patients". Brit J Gen Pract60 (576): 483488.doi:10.3399/bjgp10X514729. PMC2894402. PMID20594429.
Rabe KF, Hurd S, Anzueto A, et al. (2007). "Global Strategy for the Diagnosis, Management, and Prevention ofChronic Obstructive Pulmonary Disease: GOLD Executive Summary". Am. J. Respir. Crit. Care Med.176 (6):53255.
Mathers CD, Loncar D (November 2006). "Projections of Global Mortality and Burden of Disease from 2002 to
2030". PLoS Med.3 (11): e442. doi:10.1371/journal.pmed.0030442. PMC1664601. PMID17132052.
Burrows B, Fletcher CM, Heard BE, et al(1966). "The emphysematous and bronchial types of chronic airwaysobstruction. A clinicopathological study of patients in London and Chicago". Lancet87: 8305.
Kitaguchi Y, Fujimoto K, Kubo K, Honda T (October 2006). "Characteristics of COPD phenotypes classified
according to the findings of HRCT". Respir Med100 (10): 174252. doi:10.1016/j.rmed.2006.02.003. PaolettiM, Camiciottoli G, Meoni E, et al. (December 2009). "Explorative data analysis techniques and unsupervisedclustering methods to support clinical assessment of Chronic Obstructive Pulmonary Disease (COPD)
phenotypes". J Biomed Inform42 (6): 101321. doi:10.1016/j.jbi.2009.05.008.
Petty TL (2002). "COPD: clinical phenotypes". Pulm Pharmacol Ther15 (4): 34151.
Lacasse Y, Brosseau L, Milne S, et al. (2002). Lacasse, Yves. ed. "Pulmonary rehabilitation for chronicobstructive pulmonary disease". Cochrane database of systematic reviews (Online) (3): CD003793
Dietary Supplement Fact Sheet: Vitamin D". Office of Dietary Supplements (ODS). National Institutes of Health(NIH).
Chung, M; Balk, EM, Brendel, M, Ip, S, Lau, J, Lee, J, Lichtenstein, A, Patel, K, Raman, G, Tatsioni, A,
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2217523http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2217523http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2894402http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2894402http://en.wikipedia.org/wiki/Digital_object_identifierhttp://dx.doi.org/10.3399/bjgp10X514729http://en.wikipedia.org/wiki/PubMed_Centralhttp://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=2894402http://en.wikipedia.org/wiki/PubMed_Identifierhttp://www.ncbi.nlm.nih.gov/pubmed/20594429http://dx.plos.org/10.1371/journal.pmed.0030442http://dx.plos.org/10.1371/journal.pmed.0030442http://en.wikipedia.org/wiki/Digital_object_identifierhttp://dx.doi.org/10.1371/journal.pmed.0030442http://en.wikipedia.org/wiki/PubMed_Centralhttp://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=1664601http://en.wikipedia.org/wiki/PubMed_Identifierhttp://www.ncbi.nlm.nih.gov/pubmed/17132052http://linkinghub.elsevier.com/retrieve/pii/S0954-6111(06)00064-3http://linkinghub.elsevier.com/retrieve/pii/S0954-6111(06)00064-3http://en.wikipedia.org/wiki/Digital_object_identifierhttp://dx.doi.org/10.1016/j.rmed.2006.02.003http://linkinghub.elsevier.com/retrieve/pii/S1532-0464(09)00080-Xhttp://linkinghub.elsevier.com/retrieve/pii/S1532-0464(09)00080-Xhttp://linkinghub.elsevier.com/retrieve/pii/S1532-0464(09)00080-Xhttp://en.wikipedia.org/wiki/Digital_object_identifierhttp://dx.doi.org/10.1016/j.jbi.2009.05.008http://linkinghub.elsevier.com/retrieve/pii/S1094-5539(02)90380-9http://ods.od.nih.gov/factsheets/vitamind/http://en.wikipedia.org/wiki/National_Institutes_of_Healthhttp://en.wikipedia.org/wiki/National_Institutes_of_Healthhttp://ods.od.nih.gov/factsheets/vitamind/http://linkinghub.elsevier.com/retrieve/pii/S1094-5539(02)90380-9http://dx.doi.org/10.1016/j.jbi.2009.05.008http://en.wikipedia.org/wiki/Digital_object_identifierhttp://linkinghub.elsevier.com/retrieve/pii/S1532-0464(09)00080-Xhttp://linkinghub.elsevier.com/retrieve/pii/S1532-0464(09)00080-Xhttp://linkinghub.elsevier.com/retrieve/pii/S1532-0464(09)00080-Xhttp://dx.doi.org/10.1016/j.rmed.2006.02.003http://en.wikipedia.org/wiki/Digital_object_identifierhttp://linkinghub.elsevier.com/retrieve/pii/S0954-6111(06)00064-3http://linkinghub.elsevier.com/retrieve/pii/S0954-6111(06)00064-3http://www.ncbi.nlm.nih.gov/pubmed/17132052http://en.wikipedia.org/wiki/PubMed_Identifierhttp://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=1664601http://en.wikipedia.org/wiki/PubMed_Centralhttp://dx.doi.org/10.1371/journal.pmed.0030442http://en.wikipedia.org/wiki/Digital_object_identifierhttp://dx.plos.org/10.1371/journal.pmed.0030442http://dx.plos.org/10.1371/journal.pmed.0030442http://www.ncbi.nlm.nih.gov/pubmed/20594429http://en.wikipedia.org/wiki/PubMed_Identifierhttp://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=2894402http://en.wikipedia.org/wiki/PubMed_Centralhttp://dx.doi.org/10.3399/bjgp10X514729http://en.wikipedia.org/wiki/Digital_object_identifierhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2894402http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2894402http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2217523http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2217523http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2217523http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2217523